The DOI matches its Crossref record; 241 of the 241 references it cites were found in a registry or an index.
Oxidative Stress, Redox Signaling, and Metal Chelation in Anthracycline Cardiotoxicity and Pharmacological Cardioprotection
Open accessAbstract
SIGNIFICANCE: Anthracyclines (doxorubicin, daunorubicin, or epirubicin) rank among the most effective anticancer drugs, but their clinical usefulness is hampered by the risk of cardiotoxicity. The most feared are the chronic forms of cardiotoxicity, characterized by irreversible cardiac damage and congestive heart failure. Although the pathogenesis of anthracycline cardiotoxicity seems to be complex, the pivotal role has been traditionally attributed to the iron-mediated formation of reactive oxygen species (ROS). In clinics, the bisdioxopiperazine agent dexrazoxane (ICRF-187) reduces the risk of anthracycline cardiotoxicity without a significant effect on response to chemotherapy. The prevailing concept describes dexrazoxane as a prodrug undergoing bioactivation to an iron-chelating agent ADR-925, which may inhibit anthracycline-induced ROS formation and oxidative damage to cardiomyocytes. RECENT ADVANCES: A considerable body of evidence points to mitochondria as the key targets for anthracycline cardiotoxicity, and therefore it could be also crucial for effective cardioprotection. Numerous antioxidants and several iron chelators have been tested in vitro and in vivo with variable outcomes. None of these compounds have matched or even surpassed the effectiveness of dexrazoxane in chronic anthracycline cardiotoxicity settings, despite being stronger chelators and/or antioxidants. CRITICAL ISSUES: The interpretation of many findings is complicated by the heterogeneity of experimental models and frequent employment of acute high-dose treatments with limited translatability to clinical practice. FUTURE DIRECTIONS: Dexrazoxane may be the key to the enigma of anthracycline cardiotoxicity, and therefore it warrants further investigation, including the search for alternative/complementary modes of cardioprotective action beyond simple iron chelation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–241 of 241
Deng, S., Krüger, A., Schmidt, A. G., Metzger, A., Yan, T., Gödtel‐Armbrust, U., Hasenfuss, G. P., Brünner, F., & Wojnowski, L. (2009) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-009-0407-y · Cited by 38
Ruiz‐Ruiz, C., Robledo, G., Cano, E., Redondo, J. M., & López‐Rivas, A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304397200 · Cited by 37
The Role of Iron and Iron Chelators in Anthracycline Cardiotoxicity
Hershko, C., Link, G., Tzahor, M., & Pinson, A. (1993) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199309086997 · Cited by 37
Amelioration of doxorubicin-induced cardiotoxicity by deferiprone in rats
Ammar, E. M., Said, S. A., Suddek, G. M., & El-Damarawy, S. L. (2011) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y11-020 · Cited by 36
Phase I trials of dexrazoxane and other potential applications for the agent.
Hoff, D. D. V. (1998) · PubMed · Cited by 36
Pyridoxal Isonicotinoyl hydrazone and its analogues
Buss, J. L., Hermes‐Lima, M., & Ponka, P. (2002) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-0593-8_11 · Cited by 35
Hasinoff, B. B., Yalowich, J. C., Ling, Y., et al. (1996) · Anti-Cancer Drugs · doi:10.1097/00001813-199607000-00011 · Cited by 35
Dexrazoxane (ICRF-187) Protects Cardiac Myocytes Against Hypoxia-Reoxygenation Damage
Hasinoff, B. B. (2002) · Cardiovascular Toxicology · doi:10.1385/ct:2:2:111 · Cited by 35
Persoon-Rothert, M. (1989) · Journal of Molecular and Cellular Cardiology · doi:10.1016/0022-2828(89)90674-3 · Cited by 35
Lebrecht, D., Kirschner, J., Geist, A., Haberstroh, J., & Walker, U. A. (2009) · Cardiovascular Pathology · doi:10.1016/j.carpath.2009.06.006 · Cited by 34
Schroeder, P. E., & Hasinoff, B. B. (2002) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-002-0538-z · Cited by 33
Štěrba, M., Popelová, O., Šimůnek, T., Mazurová, Y., Potáčová, A., Adamcová, M., Němečková, I., Mertlíková‐Kaiserová, H., Palička, V., Poňka, P., et al. (2007) · Toxicology · doi:10.1016/j.tox.2007.03.020 · Cited by 33
Self-citationSchroeder, P. E., & Hasinoff, B. B. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.005546 · Cited by 33
Kovařı́ková, P., Klimeš, J., Štěrba, M., Popelová, O., Mokrý, M., Geršl, V., & Poňka, P. (2005) · Journal of Separation Science · doi:10.1002/jssc.200500077 · Cited by 32
Self-citationThomas, C., Vile, G. F., & Winterbourn, C. C. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90005-h · Cited by 31
Cardioprotective Effects of Subcutaneous Ebselen against Daunorubicin‐Induced Cardiomyopathy in Rats
Saad, S. Y., Najjar, T. A. O., & Arafah, M. (2006) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2006.pto_523.x · Cited by 30
Elbl, L., Hrstková, H., Tomášková, I., & Michálek, J. (2005) · Supportive Care in Cancer · doi:10.1007/s00520-005-0858-8 · Cited by 30
Rao, V. A., Zhang, J., Klein, S. R., Espandiari, P., Knapton, A. D., Dickey, J. S., Herman, E. H., & Shacter, E. B. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1587-y · Cited by 29
New aspects in probucol cardioprotection against doxorubicin-induced cardiotoxicity
El‐Demerdash, E., Ali, A. A., Sayed‐Ahmed, M. M., & Osman, A. M. (2003) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0676-y · Cited by 29
Cardiac phosphoproteome reveals cell signaling events involved in doxorubicin cardiotoxicity
Gratia, S., Kay, L., Michelland, S., Sève, M., Schlattner, U., & Tokarska-Schlattner, M. (2012) · Journal of Proteomics · doi:10.1016/j.jprot.2012.02.004 · Cited by 28
Mladěnka, P., Kalinowski, D. S., Hašková, P., Bobrovová, Z., Hrdina, R., Šimůnek, T., Nachtigal, P., Semecký, V., Vávrová, J., Holečková, M., et al. (2008) · Chemical Research in Toxicology · doi:10.1021/tx800331j · Cited by 28
Self-citationImondi, A. R. (1998) · PubMed · Cited by 27
Timing of treatment with ICRF-187 and its effect on chronic doxorubicin cardiotoxicity
Herman, E. H., & Ferrans, V. J. (1993) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00685888 · Cited by 26
Deferasirox removes cardiac iron and attenuates oxidative stress in the iron‐overloaded gerbil
Al‐Rousan, R. M., Paturi, S., Laurino, J. P., Kakarla, S. K., Gutta, A. K., Walker, E. M., & Blough, E. R. (2009) · American Journal of Hematology · doi:10.1002/ajh.21487 · Cited by 26
The use of liposomal anthracycline analogues for childhood malignancies: A systematic review
Sieswerda, E., Kremer, L. C. M., Caron, H. N., & van Dalen, E. C. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.03.024 · Cited by 26
Diop, N. K., Vitellaro, L. K., Arnold, P., Shang, M., & Marusak, R. A. (2000) · Journal of Inorganic Biochemistry · doi:10.1016/s0162-0134(00)00013-1 · Cited by 25
The iron chelator Dp44mT does not protect myocytes against doxorubicin
Hasinoff, B. B., & Patel, D. (2009) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2009.05.007 · Cited by 25
Frederine, a new and promising protector against doxorubicin-induced cardiotoxicity.
van Acker, F. A. A., Boven, E., Kramer, K., Haenen, G. R. M. M., Bast, A., & van der Vijgh, W. J. F. (2001) · PubMed · Cited by 23
Deferiprone protects the isolated atria from cardiotoxicity induced by doxorubicin
Xu, L., Jin, L., Pan, H., Zhang, A.-Z., Wei, G., Li, P., & Lu, W. (2006) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2006.00409.x · Cited by 23
Prevention of Postasphyxia Electroretinal Dysfunction with a Pyridoxal Hydrazone
Bhattacharya, M., Poňka, P., Hardy, P., Hanna, N., Varma, D. R., Lachapelle, P., & Chemtob, S. (1997) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(96)00274-2 · Cited by 22
Daunorubicin therapy is associated with upregulation of E3 ubiquitin ligases in the heart
Sishi, B., Bester, D. J., Wergeland, A., Loos, B., Jonassen, A. K., van Rooyen, J., & Engelbrecht, A. (2012) · Experimental Biology and Medicine · doi:10.1258/ebm.2011.011106 · Cited by 20
Herman, E., El-Hage, A. N., Creighton, A. M., Witiak, D. T., & Ferrans, V. J. (1985) · The Journal of Urology · doi:10.1016/s0022-5347(17)47336-8 · Cited by 19
Zhou, L., Sung, R. Y. T., Li, K., Pong, N. H., Xiang, P., Shen, J., Ng, P. C., & Chen, Y. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2010.07.015 · Cited by 17
Long-term effects of 7-monohydroxyethylrutoside (monoHER) on DOX-induced cardiotoxicity in mice
Bruynzeel, A. M. E., Vormer-Bonne, S., Bast, A., Niessen, H. W. M., & van der Vijgh, W. J. F. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0395-2 · Cited by 17
Robison, T. W., Giri, S. N., & Wilson, D. W. (1989) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.2570040204 · Cited by 15
Kovařı́ková, P., Klimeš, J., Štěrba, M., Popelová, O., Geršl, V., & Poňka, P. (2006) · Journal of Chromatography B · doi:10.1016/j.jchromb.2006.04.020 · Cited by 14
Self-citationde Beer, E. L., Bottone, A. E., van Rijk, M. C., van der Velden, J., & Voest, E. E. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704621 · Cited by 13
Dexrazoxane provided moderate protection in a catecholamine model of severe cardiotoxicity
Zatloukalová, L., Filipský, T., Mladěnka, P., Semecký, V., Macáková, K., Holečková, M., Vávrová, J., Palička, V., & Hrdina, R. (2012) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y2012-009 · Cited by 10
Pharmacokinetics of representative 3-hydroxypyridin-4-ones in rabbits: CP20 and CP94.
Fredenburg, A. M., Wedlund, P. J., Skinner, T. L., Damani, L. A., Hider, R. C., & Yokel, R. A. (1993) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08089-4 · Cited by 10
Simunek, T., Sterba, M., Popelova, O., Kaiserova, H., Potacova, A., Adamcova, M., Mazurova, Y., Ponka, P., & Gersl, V. (2008) · Hemoglobin · doi:10.1080/03630260701680276 · Cited by 9
Hrdina, R., Geršl, V., Klimtová, I., et al. (2002) · Acta Medica (Hradec Kralove Czech Republic) · doi:10.14712/18059694.2019.63 · Cited by 3
Self-citation
Cited by
Mitochondria and Mitophagy: The Yin and Yang of Cell Death Control
Kubli, D. A., & Gustafsson, Å. B. (2012) · Circulation Research · doi:10.1161/circresaha.112.265819 · Cited by 796
Doxorubicin Blocks Cardiomyocyte Autophagic Flux by Inhibiting Lysosome Acidification
Li, D. L., Wang, Z. V., Ding, G., Tan, W., Luo, X., Criollo, A., Xie, M., Jiang, N., May, H., Kyrychenko, V., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.017443 · Cited by 464
Cappetta, D., De Angelis, A., Sapio, L., Prezioso, L., Illiano, M., Quaini, F., Rossi, F., Berrino, L., Naviglio, S., & Urbanek, K. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/1521020 · Cited by 350
Zordoky, B. N. M., Robertson, I. M., & Dyck, J. R. B. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.10.016 · Cited by 335
Gorini, S., De Angelis, A., Berrino, L., Malara, N., Rosano, G., & Ferraro, E. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/7582730 · Cited by 325
Metadata
- Authors
- Štěrba, M., Popelová, O., Vávrová, A., Jirkovský, E., Kovaříková, P., Geršl, V., & Šimůnek, T.
- Venue
- Antioxidants & Redox Signaling
- Publisher
- SAGE Publications
- Published
- 2013-03-10
- Volume
- 18
- Issue
- 8
- Pages
- 899-929
- ISSN
- 1523-0864 (ISSN-L)
- 1557-7716
- OpenAlex
- W2036225919
- Cited by
- 329
- References
- 241
- FWCI
- 12.85
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.